Los Angeles Capital Management LLC Takes $61,000 Position in Arbutus Biopharma Corporation $ABUS

Los Angeles Capital Management LLC bought a new position in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 19,655 shares of the biopharmaceutical company’s stock, valued at approximately $61,000.

Several other institutional investors also recently bought and sold shares of ABUS. EntryPoint Capital LLC acquired a new stake in shares of Arbutus Biopharma during the first quarter worth about $65,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Arbutus Biopharma in the second quarter valued at approximately $112,000. Assenagon Asset Management S.A. purchased a new position in Arbutus Biopharma in the second quarter worth approximately $122,000. XTX Topco Ltd grew its holdings in Arbutus Biopharma by 37.7% during the 1st quarter. XTX Topco Ltd now owns 72,412 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 19,831 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Arbutus Biopharma by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 76,031 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 6,371 shares during the last quarter. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Stock Performance

Shares of NASDAQ:ABUS opened at $4.45 on Wednesday. Arbutus Biopharma Corporation has a one year low of $2.70 and a one year high of $5.10. The stock has a market capitalization of $855.84 million, a price-to-earnings ratio of -15.34 and a beta of 1.07. The company has a 50-day simple moving average of $4.48 and a 200-day simple moving average of $3.77.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $0.53 million for the quarter, compared to analyst estimates of $1.31 million. Arbutus Biopharma had a negative return on equity of 59.28% and a negative net margin of 352.24%. As a group, research analysts forecast that Arbutus Biopharma Corporation will post -0.39 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on ABUS. Wall Street Zen cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. Chardan Capital reissued a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday, November 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Arbutus Biopharma presently has an average rating of “Hold” and a consensus price target of $5.00.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.